21:00 , Apr 12, 2018 |  BC Innovations  |  Translation in Brief

Viral variant vaccine

A team from Duke-NUS Medical School rapidly developed a live-attenuated Zika vaccine candidate by exploiting genetic errors to identify a strain with high viremia and reduced propagation. The approach could speed development of live vaccines...
22:11 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Patient sample, cell culture and mouse studies suggest inhibiting IRF3 could help treat gastric cancer. In patient samples, high levels of IRF3 tumor RNA and protein correlated with tumor size and poor survival....
01:19 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Age-related macular degeneration (AMD) Patient sample, cell culture and mouse studies suggest inhibiting cGAS, CASP4, GSDMD, IFNB1, IFNAR1, IRF3 or STAT2 could help treat geographic atrophy. In tissue samples from patients, levels of cGAS, GSDMD...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
20:05 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new targets to treat myocardial infarction

In a paper published Monday in Nature Medicine, researchers from Massachusetts General Hospital and colleagues identified the mechanism behind an elevated immune response after myocardial infarction and suggested interferon regulatory factor 3 (IRF3), interferon alpha/beta...
19:51 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Mouse studies suggest inhibiting IRF3, IFNAR1, or cGAS could help treat MI. In infarcted heart tissue from a mouse model of MI, IRF3 expression was higher than in heart tissue from normal...
21:00 , Aug 17, 2017 |  BC Innovations  |  Translation in Brief

Stopping the invasion

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it...
17:44 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could help treat glioblastoma multiforme (GBM). In mouse brain slices co-cultured with a patient-derived GBM cell line, vector-mediated constitutively active IRF3...
07:00 , Jul 28, 2016 |  BC Innovations  |  Targets & Mechanisms

Making sense of sensors

Two new pathways are emerging as viable options for harnessing nucleic acid sensors in immuno-oncology, offering an alternative to the toll-like receptors (TLRs) that paved the way. By activating STING or RIG-I, researchers are expanding...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Mice with knockout of interferon-related genes as models of Zika infection

Disease models TECHNOLOGY: Transgenics and knockouts Two mouse models with knockout of interferon-related genes could be useful for screening therapies to treat Zika infection. In mice with knockout of interferon regulatory factor 3 (IRF3), IRF5 and IRF7,...